Navigation Links
Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer
Date:2/14/2013

BRISBANE, Calif., Feb. 14, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Sean P. Nolan has joined InterMune as Executive Vice President and Chief Business Officer.

(Logo:  http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

In this newly created position, Mr. Nolan will lead the creation and establishment of InterMune's U.S. Commercial, Business Development and Global Marketing groups. He will also oversee InterMune's Canadian operations and the company's Manufacturing Operations and Supply Chain Management. Mr. Nolan will report to Dan Welch , Chairman, Chief Executive Officer and President of InterMune.

Mr. Welch said, "Sean will play a key role in InterMune's future as our Esbriet sales continue to grow globally, we move closer to the anticipated approval and launch of Esbriet in the United States and as we prepare to develop our business. I am confident that Sean will provide the broad and deep commercial and business experience, energy and drive that are essential during this exciting period of growth and change for our company."

Mr. Nolan began his career at Abbott Laboratories in 1991 and during a period of 13 years served in a variety of marketing and sales leadership positions. In 2004, he joined Ovation Pharmaceuticals, a privately held specialty pharmaceutical company focused on the development and commercialization of therapies to treat rare diseases. At Ovation, Sean developed and implemented the commercial strategies for the orphan drug pipeline and subsequently led the organization's effort that resulted in FDA approval of the company's lead compound. Ovation was acquired by the Danish pharmaceutical company, H. Lundbeck in 2009. After leading the company integration process, Mr. Nolan served as President of the newly created U.S. entity of Lundbeck. While at Lundbeck, Mr. Nolan served on the board of the Tuberous Sclerosis Alliance, and was co-chair of the Rare and Specialty Disease Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Mr. Nolan joins InterMune from Reata Pharmaceuticals, where he most recently served as Vice President and Chief Commercial Officer and built a commercial operation to support the company's lead product. 

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved  for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AMRI Appoints Michael Nolan Vice President, Chief Financial Officer and Treasurer
2. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
3. Dr. Mickey Urdea Joins Pressure BioSciences Board of Directors
4. Natalie Douglas, CEO of Idis, Joins Global Genes
5. RARE Project Board of Directors
6. Breast Imaging Specialist Dr. Catherine D. Buhler Joins Radiologic Associates of Fredericksburg
7. Stephen Ondra, M.D., Joins Health Care Service Corporation As Enterprise Chief Medical Officer
8. Attorney Ellen Presby Joins The Nemeroff Law Firm In Dallas
9. Kevin Johnson Joins United Allergy Services Board Of Directors
10. Robert Funari Joins NxStage Board of Directors
11. B. Braun Joins National Health Organization Supporting Environmental Practices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 23, 2017 7D Surgical announced today ... the U.S. Food and Drug Administration (FDA) and ... the North American commercial launch of its innovative ... surgery, the 7D Surgical System.  ... technologies and machine vision algorithms to eliminate the ...
(Date:1/23/2017)... Jan. 23, 2017 The American Pharmacists Association ... Pharmacy and Medically Underserved Areas Enhancement Act ... The legislation, which was previously introduced in the 114 ... to health care through pharmacists and their patient care ... Brett Guthrie (R-KY), G.K. Butterfield ...
(Date:1/23/2017)... , January 23, 2017 Stock-Callers.com today ... Inc. (NASDAQ: CPRX ), Sophiris Bio Inc. (NASDAQ: ... MNTA ), and Agile Therapeutics Inc. (NASDAQ: AGRX ... turned somewhat lower in late trade on Friday, January 20 ... about 0.3%, while shares of health care companies in the ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... ... METTLER TOLEDO has announced the availability of a new ... . , Crystallization is a common step used during the synthesis ... spend more time developing better intermediate and final crystallization steps. By adopting ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and Research ... Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high quality research ...
(Date:1/23/2017)... ... ... Under Blankets”: an entrancing story about one woman's travels through the wilderness of ... published author, Kimberly Mitchell, who earned her bachelor’s degree in English education at the ... degree in education in the field of curriculum and instruction. Kimberly’s passion for writing ...
(Date:1/22/2017)... California (PRWEB) , ... January 22, 2017 , ... "Photo ... Cloud to create a beautiful 3D slideshow with complete ease," said Christina Austin - ... Generators browser to place in the FCPX timeline. Presets include scenes with ...
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of oats in China, ... owner and founder. As Oat is recognized globally as one of the healthiest cereals, ... he believes it is a move to sow the seed of good karma. Buddhism ...
Breaking Medicine News(10 mins):